Breast cancer is the most frequent carcinoma in women with a lifetime risk affecting ∼12% of the total population ([@bib19]). The biology of the disease is heterogeneous and ∼20% of breast carcinomas overexpress the HER2/c-erbB-2 oncoprotein ([@bib5]). This receptor, a member of the epidermal growth factor receptor family, has tyrosine kinase activity and is located at the breast cancer cell membrane. This dimerises with all members of the family, when they bind to various cognate ligands. This dimerisation induces autophosphorylation of tyrosine residues and initiates a signalling cascade within the cell. This includes activation of MAP-kinase, phosphoinositide 3-kinase/Akt and protein kinase-C, among others. As a result, tumours with a high percentage of HER2-positive cells assume an aggressive clinical behaviour so that overexpression is linked with poor post-operative outcome and increased resistance to chemotherapy ([@bib5]). The introduction into clinical practice of anti-HER2 monoclonal antibodies or specific inhibitors of HER2 tyrosine kinase activity has resulted in important prolongation of overall survival, whether these are used as an adjuvant therapy, a component of chemotherapy for metastatic disease or as a component of neoadjuvant chemotherapy in locally advanced HER2 positive disease ([@bib3]).

Nevertheless, only 35% of advanced HER2 positive tumours respond to anti-HER2 therapies and 70% of responders will develop disease progression during therapy ([@bib5]). Intrinsic resistance of cancer cells is certainly a major determinant of the efficacy of Trastuzumab. PTEN suppression, SRC nonmembrane tyrosine kinase overexpression and constitutive PIK3/Akt activation have been identified as components of intrinsic resistance ([@bib16]; [@bib17]; [@bib23]). Steric effects like HER2 mutations that lack the extracellular domain or have internal domain mutations are another mechanism. Overexpression of other tyrosine kinase receptors, like c-met, may bypass the HER2 signalling pathway blockage ([@bib15]). Identification of targetable biological pathways involved in anti-HER2 therapy resistance would make a contribution to the prolongation of life expectancy of patients with HER2+ metastatic disease or even increase survival rates in case of patients with locoregional disease.

In the current prospective clinicopathological study we assessed three aspects of response to Trastuzumab: (1) the ability of baseline features of tumour metabolism assessed with PET-CT and immunohistochemistry for GLUT1, HIF1*α*, cancer cell proliferation (Ki67) and autophagy hallmarks LC3A and LC3B to predict early response to Trastuzumab assessed by changes in Ki67 and PET FDG; (2) the baseline variables and their relation to pathological response to Trastuzumab and (3) the change in variables after Trastuzumab alone and their relation to pathological response to Trastuzumab and taxol.

Materials and Methods
=====================

Twenty-eight patients with locally advanced primary breast cancer, diagnosed using incisional biopsy, were prospectively scheduled to received 1 cycle of Trastuzumab (Herceptin, Roche, Milan, Italy) 8 mg per kg iv on day 0, before starting any other treatment. After 21 days Tru-cut biopsy was performed. Patients and disease characteristics are shown in [Table 1](#tbl1){ref-type="table"}. Patients were treated thereafter with four cycles of chemotherapy (Trastuzumab 6 mg per kg iv and paclitaxel 80 mg m^−2^ per week, q21) till definitive surgery. Quadrantectomy or radical mastectomy was performed when indicated in association with full axillary node dissection.

All patients were required to have at study inclusion a baseline Eastern Cooperative Oncology Group (ECOG) performance status ⩽2, a neutrophil count ⩾1.5 × 10^9^ per litre, a platelet count \>100 × 10^9^ per litre, normal hepatic and renal function as determined by serum creatinine \<1.5 times the upper limit of normal and creatinine clearance \>60 ml per minute and no acute or chronic infections or inflammatory diseases. Any chemotherapy or hormone therapy was excluded during the 'biological window\' opportunity treatment (3 weeks). Patients recently (\<1 week) or simultaneously treated with steroids or diabetic patients were considered ineligible for the study. All patients received Trastuzumab on an outpatient basis and provided written informed consent prior to screening. The institutional review board approved this prospective study.

Tumour dimensions were measured clinically and on FDG PET/CT scan before administration of Trastuzumab and on post-therapy day 21. The SUVmax was also assessed as a marker of tumour metabolic activity. The results of chemotherapy were quantified as the post-operative pathologically measured tumour dimensions.

^18^FDG-PET/CT
--------------

The ^18^FDG-PET scans were carried out using a Discovery ST GE Healthcare PET/CT scanner (GE Healthcare, Milwaukee, WI, USA; CT eight-slice) and performed at baseline, after 21±2 days of treatment (window of opportunity based on Trastuzumab) and before definitive surgery. Two experienced PET readers analysed the 18FDG-PET/CT images independently. Standardised uptake values (SUVs) were calculated. The observers were blinded for any clinical data including the site of the primary tumour. Discrepancies were solved by consensus. During the study, clinicians and pathologists were blinded to the ^18^FDG-PET/TC related data.

Immunohistochemistry
--------------------

The proteins under evaluation were detected by previously standardised immunohistochemical techniques using: (i) The purified rabbit polyclonal antibody MAP1LCA (AP1805a, Abgent, San Diego, CA, USA) raised against a synthetic peptide at the C-terminal cleavage site of the human cleaved-LC3A (APG8a). This antibody was used at 1 : 20 dilution, as recently described ([@bib4]). This antibody recognises specifically the A and not the B variant in western blot experiments against human recombinant proteins LC3A (H00084557-P01, Abnova, Heidelberg, Germany) and LC3B (H00081631-P01, Abnova) ([@bib10]). (ii) The mouse monoclonal antibody (1:100; LC3B 5F10 Nanotools). This antibody recognises specifically the B and not the A variant in western blot experiments (data not shown). (iii) The Ki67 monoclonal antibody (Dako, Glostrup, Denmark) recognising the MIB1 antigen was used to assess cancer cell proliferation. This was used at a dilution of 1 : 75 and 75 min incubation. (iv) The ESEE122 mouse monoclonal antibody (University of Oxford, Oxford, UK) was used to assess the expression of HIF1*α* transcription factor, at a dilution of 1 : 20 and overnight incubation. (v) For the assessment of the glucose absorption ability of cancer cells we used the ab652 (Abcam, UK; 1 : 100) monoclonal rabbit antibody recognising the glucose transporter 1 (GLUT1) protein. This was used at a dilution of 1 : 100 and overnight incubation. (vi) HER2/c-erbB-2 membrane protein expression was assessed using the monoclonal NCL-CB11 antibody, in double immunostaining with LC3A and LC3B, so we could further assess the percentage of HERr2+ cells expressing LC3A or LC3B and the response of this subpopulation to Trastuzumab. The limited material available from the pre-chemotherapy biopsy-obtained tissue did not allow the study of eventually additional important markers related to pH regulation, respiration, glycolysis and autophagy flux.

Briefly, tissue sections were cut at 3 *μ*m from formalin-fixed paraffin-embedded tumours and mounted on poly-L-lysine coated glass slides. They were subsequently dewaxed and rehydrated in graded alcohols. Heat-induced epitope retrieval was achieved by placing the sections in citrate buffer (1 : 10 dilution, pH 7.2) and heated at 120 °C for 3 × 5 min. Endogenous peroxidase activity was neutralised using peroxidase block for 5 min. The non-specific binding was blocked by preincubation with protein block for 5 min at room temperature (Novocastra Laboratories Ltd, Newcastle upon Tyne, UK). The slides were then incubated with the primary antibodies at dilutions and times indicated above. After washes in phosphate-buffered saline (PBS) (2 × 5 min), the sections were incubated with post primary block (that enhances penetration of the subsequent polymer agent) for 30 min at room temperature (Novocastra Laboratories Ltd). They were subsequently washed in PBS for 2 × 5 min and incubated with NovoLink polymer for 30 min at room temperature (Novocastra Laboratories Ltd). This recognises mouse and rabbit immunoglobulins and detects any tissue-bound primary antibody. After thorough washing in PBS (2 × 5 min), the colour reaction was developed in 3,3′-diaminobenzidine (DAB) for 5 min. The sections were then counterstained with hematoxylin, dehydrated and mounted. In every staining run one component of the sequential staining reaction was omitted from at least one section, this usually being the omission of the primary antibody and its replacement by normal species-specific immunoglobulin-G.

Evaluation of the protein expression
------------------------------------

For LC3A and LC3B expression, the percentage of cells with strong cytoplasmic expression was recorded in all optical fields and the mean value for each case was calculated for continuous variable analysis. Double immunohistochemical staining for HER2/LC3A and HER2/LC3B was performed, so we could further assess the percentage of HER2+ cells expressing LC3A or LC3B and the response of this subpopulation to Trastuzumab.

For Ki67 cancer cell proliferation index the percentage of cells with nuclear MIB1 expression was recorded in all optical fields and the mean value for each case was calculated for continuous variable analysis. For HIF1*α* protein expression the percentage of cells with cytoplasmic and with nuclear MIB1 expression was separately assessed in all optical fields and the mean value for each case was calculated for continuous variable analysis. For GLUT1 expression the percentage of cells with membrane immunoreactivity was recorded in all optical fields and the mean value for each case was calculated for continuous variable analysis. Cytoplasmic staining was disregarded. For group analysis, the median value was taken into account to define groups of low *vs* high reactivity.

Statistical analysis
--------------------

Statistical analysis was performed using the GraphPad Prism 5.01 package (GraphPad, San Diego, CA, USA; [www.graphpad.com](http://www.graphpad.com)). The Fisher\'s exact test or the paired and unpaired two-tailed *t*-tests were used for testing relationships between categorical or continuous variable groups, as appropriate. Linear regression analysis was used to assess correlation between continuous variables. A *P*-value ⩽0.05 was considered significant.

Results
=======

Immunohistochemistry analysis
-----------------------------

The percentage of cells with strong cytoplasmic LC3A or LC3B protein expression ranged between 0 and 100 among cases (median 30). The percentage of cancer cells with double HER2/LC3A reactivity ranged from 0% to 90% (median 30). The percentage of cancer cells with double HER2/LC3B reactivity ranged from 0% to 90% (median 20). [Figure 1A--C](#fig1){ref-type="fig"} show typical images of double and single antibody reactivity on cancer cells.

Cytoplasmic HIF1*α* expression ranged from 0% to 100% (median 10), while nuclear expression ranged from 0% to 50% (median 0). [Figure 1D and E](#fig1){ref-type="fig"} shows two cases with low and high mixed HIF1*α* cytoplasmic and nuclear reactivity. Membrane GLUT1 expression was noted in 0--80% of cells (median 22). [Figure 1F and G](#fig1){ref-type="fig"} shows a typical image of low and high membrane GLUT1 expression. For proliferation index, the nuclear Ki67 expression was used by grouping cases according to the median value of 28% of positive cells (⩽28 *vs* \>28).

Linear regression analysis between variables revealed interesting correlations. The LC3A/HER2+ cell population was correlated with HIF1*α* expression (*P*=0.01, *r*=0.45), while GLUT1 and LC3B expression correlated with Ki67 proliferation index (*P*=0.01, *r*=0.47 and *P*=0.01, *r*=0.45, respectively; [Figure 2A--C](#fig2){ref-type="fig"}. A significant association between LC3A and LC3B was also found (*P*=0.01, *r*=0.38).

PET *vs* histology and immunohistochemical variables
----------------------------------------------------

Tumour dimensions as assessed by PET imaging ranged from 10 to 68 mm (median 23 mm). In linear regression analysis, PET dimensions were also correlated with advanced T-stage (*P*=0.01, *r*=0.21), high histology grade (*P*=0.05, *r*=0.38) and with LC3B expression (*P*=0.005, *r*=0.27). In group analysis (T1, 2 *vs* T3, 4), the association of PET dimensions with T-stage did not reach significance (*P*=0.09; [Figure 2D](#fig2){ref-type="fig"}), whereas a strong correlation with high Ki67 proliferation index was documented (*P*=0.0009; [Figure 2E](#fig2){ref-type="fig"}). Similarly, tumours with high LC3B levels were significantly larger in PET images (*P*=0.05; [Figure 2F](#fig2){ref-type="fig"}) No significant association was recorded for the rest of the variables.

SUVmax ranged from 2.1 to 15.7 (median 7.5) and linear regression analysis showed a correlation with PET size (*P*=0.01, *r*=0.48). The only other association was a correlation with the percentage of HER2-positive cells (*P*=0.05, *r*=0.33). There was no association with T-stage, Ki67 index and LC3B staining ([Figure 2D--F](#fig2){ref-type="fig"}) or with any other variable.

Response to Trastuzumab
-----------------------

Administration of Trastuzumab significantly reduced overall tumour dimensions, whether assessed clinically (39.9±2 *vs* 28.7±22; *P*=0.01) or with PET (28.7±2 *vs* 23.2±1; *P*=0.004); [Figure 3A](#fig3){ref-type="fig"}. There was also a significant reduction of the SUV values (7.8±3 *vs* 4.7±3; *P*\<00001); [Figure 3B](#fig3){ref-type="fig"}. [Figure 3C](#fig3){ref-type="fig"} shows individual changes of SUVmax, before and after Trastuzumab administration.

The effect of the pathology variables on response to Trastuzumab and on SUVmax was studied. The percentage of clinical or PET-assessed tumour response was calculated as the ratio '(initial dimensions−final dimensions)/initial dimensions\'. A similar ratio was also calculated for the SUV reduction. Using this ratio, we assessed the percentage of tumour (or SUV) reduction after Trastuzumab administration. Linear regression analysis of response revealed a significant association of the percentage reduction of clinical dimensions with percentage reduction of PET dimension and SUV ([Figure 3D and E](#fig3){ref-type="fig"}). A significant inverse association of the baseline percentage of HIF1*α*+ cells with reduction of clinical dimensions was confirmed ([Figure 3F](#fig3){ref-type="fig"}), showing an important association of HIF1*α* expression with resistance of breast cancer to Trastuzumab therapy. Group analysis, using 50% reduction as a cutoff point to define tumours with low *vs* high HIF1*α* reactivity, confirmed a significant association of high HIF1*α* with resistant tumours (*P*=0.01); [Figure 3G](#fig3){ref-type="fig"}. The association of SUVmax reduction with the percentage of HER2+ cells was not significant (*P*=0.08; [Figure 3H](#fig3){ref-type="fig"}).

Effect of Trastuzumab on the expression of autophagy, proliferation markers and HER2
------------------------------------------------------------------------------------

Tru-cut biopsies obtained on day 21 following administration of Trastuzumab were immunohistochemically analysed. Administration of Trastuzumab resulted in a significant decrease of the proliferation index (29.7±15 *vs* 24.4±15; *P*=0.004), and of GLUT1 expression (28±22 *vs* 13±18; *P*=0.04); [Figure 4A](#fig4){ref-type="fig"}), whereas there was no significant effect on HIF1*α* expression (42±36 *vs* 36±35; *P*=0.75).

A significant reduction of the HER2+ cell population in the tumours was noted (89±21 vs 70±38; *P*=0.01; [Figure 4B](#fig4){ref-type="fig"}) after exposure to Trastuzumab. The percentage of cells with LC3A expression was significantly increased after therapy (26±21 *vs* 49±26; *P*=0.005; [Figure 4B](#fig4){ref-type="fig"}). There was no difference in LC3B-positive cells (31±27 *vs* 27±24; *P*=0.85; [Figure 4B](#fig4){ref-type="fig"}). In double immunostaining, focusing on the total cell population, the percentage of cells expressing simultaneously HER2 and LC3A was increased after the administration of Trastuzumab (30±23 *vs* 43±29; *P*=0.01; [Figure 4C](#fig4){ref-type="fig"}). Such a difference was not shown for the HER2+/LC3B cell population (45±36 *vs* 49±35; *P*=0.16; [Figure 4C](#fig4){ref-type="fig"}).

Response to taxol plus Trastuzumab therapy
------------------------------------------

The response rate (RR) as assessed by comparing the maximal two-dimensional size of post-operative tumour samples with the initial (pre-Trastuzumab) clinically assessed dimensions ranged from 0% to 100%, with a median value of 70%. The RR was calculated as the ratio '(initial clinical dimensions−final surgical dimensions)/initial clinical dimensions\'. Using this value two groups were formed (low *vs* high RR). Group analysis revealed a significant association of high-baseline (pre-Trastuzumab) HIF1*α* expression with low RR (*P*=0.001) and of high-baseline PgR, but not ER, expression with high RR (*P*=0.04); [Figure 4D and E](#fig4){ref-type="fig"}. No further associations were documented.

Discussion
==========

Identification of molecular pathways involved in resistance of HER2-positive breast cancer to anti-HER2 monoclonal antibodies and molecular targeted therapies is of high clinical relevance. Effective restoration of cancer cell sensitivity would improve survival in a poor prognosis subgroup of breast cancer patients, composing ∼30% of the total patient population. Signalling pathways involving PTEN, SRC, the Akt kinase or the c-met proteins have been identified as major determinants of resistance to anti-HER2 therapies ([@bib16]; [@bib17]; [@bib23]; [@bib15]).

In the current prospective clinicopathological study we investigated metabolism and autophagy-related tumour features that could influence clinical response to Trastuzumab and to Trastuzumab plus taxol. Immunohistochemical analysis of pre-Trastuzumab tumour biopsies revealed that a tumour subpopulation of HER2+/LC3A+ cells, that is, HER2+ cells with high LC3A autophagic activity, was strongly associated with the overexpression of HIF1*α*. The direct association between HIF1a and HIF2a expression with HER2 in breast cancer has been previously reported ([@bib2]; [@bib6]). HER2 overexpression has been previously shown to directly regulate synthesis of HIF1*α* and it was shown that HIF1*α* directly induces mitophagy through BNIP3 ([@bib11]; [@bib1]). Of interest, [@bib22] demonstrate that ERBB2 requires HIF1 for tumour growth and that HIF is a major downstream regulator of HER2, protecting breast cancer cells from anoikis and metabolic stress. HIF1 and LC3 autophagy have been also shown to be involved in cancer--stem cell phenotype induction ([@bib25]). Overexpression of HIF1 and anaerobic metabolism has been persistently linked with LC3A expression in a large number of studies performed by our group in different tumour types ([@bib9]; [@bib7]; [@bib8]). Thus, there is strong evidence linking anaerobic metabolism, LC3A and HER2 expression in the literature.

Of interest, high expression of LC3B, an additional marker of autophagosomal formation, was associated with high proliferation index; the latter correlated with overexpression of glucose transporter GLUT1. Moreover, increased PET scan tumour dimensions were associated with LC3B overexpression. These are in accordance with a study by [@bib12] where LC3B was linked with high proliferation in solid tumours including breast cancer. Overall, the findings confirm a close link between hypoxia, glycolytic metabolism and active autophagic pathways in HER2+ breast cancer. However, they indicate that the autophagy pathway may have more complex links because of the heterogeneity of expression and correlations of atg8-related group of homologous proteins, LC3A and B, with the other pathways.

Comparative study of pre-Trastuzumab and post-Trastuzumab tumour biopsies obtained 21 days after administration revealed important transitions of the immunohistochemical profile. Trastuzumab therapy resulted in decrease of HER2 expression in the tumour. This was possibly a result of direct cytotoxic effect on HER2+ cells, which is supported by the reduction on tumour dimensions 21 days post-therapy. The proliferation index was sharply reduced as a result of exposure to Trastuzumab. Of interest, the LC3A and the HER2+/LC3A+ subpopulation was significantly more abundant in the post-Trastuzumab biopsies. Taking into account that the HER2+/LC3A+ cell population increases after Trastuzumab, on a background of an overall decrease of HER2+ total population, we suggest that breast cancer cells expressing LC3A are resistant to Trastuzumab cytotoxic effect and persist in post-therapy biopsies. LC3A-dependent autophagy may therefore define resistance to Trastuzumab. Of interest, two important studies in the literature support the hypothesis that autophagy is involved in breast cancer resistance to HER2-targeted therapies ([@bib21]; [@bib4]). An additional study supports that macro-autophagy is also involved in the resistance of cancer cells to tamoxifen ([@bib18]), suggesting that autophagy, and presumably LC3A-targeting agents, may prove to be of importance in both breast cancer chemotherapy and hormonal therapy.

The observation that, in contrast to LC3B, only LC3A is linked with HER2 expression and with resistance of HER2+ cells to Trastuzumab is interesting and demands further investigation. Nevertheless, LC3B is also an important autophagy marker, and was strongly associated with cancer cell proliferation and tumour dimensions, and thus growth. This emerging different biological role of the two LC3s is not surprising. Our group has persistently studied and reported that LC3A and LC3B are not at all identical. Even in normal tissues, according to immunoblotting work, the LC3A protein follows discrete patterns of LC3A-I and LC3A-II changes in liver, lung, kidney and heart tissues of mice, whereas the LC3B protein does not follow the same pattern under stressed conditions, showing a cell type-specific function of these two molecules ([@bib24]). In confocal microscopy in breast and many other cancer cell lines, LC3A and LC3B autophagosomes are not identical and present different subcellular distribution (submitted data). Moreover, a widespread confusion on the role of LC3A *vs* LC3B autophagy in cancer exists because of the usage of antibodies that either recognise both LC3 forms or erroneously are believed to recognise only LC3B ([@bib10]). In fact, there is growing evidence that the biology behind LC3A-mediated autophagy is not identical to the LC3B one. The observation that LC3A is associated with HER2 in breast cancer as noted in the current study is preliminary and will need further study. On the other hand, LC3B autophagy seems also to be important in breast cancer biology, although rather less related to HER2.

Trastuzumab induced a significant reduction of tumour size in terms of both clinical and PET measurements. SUVmax was also significantly reduced, in accordance to the reduction of tumour proliferation, as assessed with immunohistochemistry. Among the immunohistochemical variables assessed, the overexpression of HIF1*α* was strongly correlated with the resistance of breast tumours to Trastuzumab. In a recent study HIF1*α* has been shown to be essential for the growth effect of HER2 activation in breast cancer ([@bib22]). Blocking HIF1*α* helped to overcome resistance of hepatoma or lung cancer cells to multikinase or EGFR inhibitors ([@bib14]; [@bib13]). In our study, HIF1*α* was further found to be the only important factor predicting poor response of HER2-positive tumours to Trastuzumab plus Taxol, which may a direct effect on increasing intrinsic cancer cell chemoresistance. Indeed, this latter effect of HIF1*α* has been confirmed for cisplatin and doxorubicin in lung cancer cells ([@bib20]). As the HIF1*α* expression did not change significantly on Trastuzumab, even though the percentage of HER2- and GLUT1 (a HIF1*α* target gene)-positive cells went down, this implies additional mechanisms besides HER2 or hypoxia driving HIF1*α* (e.g., other upstream signalling pathways such as Akt and mTOR). The relation of PgR with overall response to Trastuzumab plus Taxol demands further investigation.

The results of the current study, although based on limited material and being certainly of preliminary nature, provide clinical evidence to add to previous experimental data that support a role of autophagy as a contributor to resistance of HER2-positive breast cancer to Trastuzumab. Moreover, the study suggests that HIF1*α* expression may serve as a baseline biomarker of resistance to Trastuzumab. The HER2+/LC3A+ phenotype, which often overexpressed HIF1*α*, was revealed as a major subpopulation refractory to Trastuzumab alone. This suggests that LC3A and HIF1*α*-targeting therapies may prove critical for the augmentation of anti-HER2 therapy efficacy. Further experimental studies are now needed to follow up these observations before scheduling randomised trials investigating the value of autophagy inhibitors in trastuzumab-based chemotherapy.
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![**Immunohistochemical images before therapy.** Double immunostaining for LC3A (brown) and HER2 (red) proteins showing (**A**) membrane HER2 overxpression on a background of low LC3A cytoplasmic reactivity; (**B**) cytoplasmic LC3A expression with lack of HER2 membrane expression; (**C**) HER2 membrane expression with intense cytoplasmic LC3A expression. (**D**, **E**) show low and high cytoplasmic/nuclear expression of HIF1*α* (brown staining) respectively. (**F**, **G**) show low and high membrane GLUT1 expression, respectively.](bjc2014196f1){#fig1}

![**Linear regression between immunohistochemical variables as assessed before therapy between the percentage of LC3A+/HER2+ and HIF1*α*+ cells (**A**), the percentage of GLUT1+ and Ki67+ cancer cells (**B**) and the percentage of LC3B+ and Ki67+ cancer cells (**C**) is shown in **A**--**C**, respectively.** Group analysis between PET dimensions, SUVmax and T-stage, Ki67 proliferation index and LC3B expression is shown in **D**--**F**), respectively.](bjc2014196f2){#fig2}

![**Reduction of PET dimensions and of SUVmax after one cycle of Trastuzumab therapy is shown in A, B and C, respectively.** Linear regression analysis of reduction of clinical dimensions *vs* PET dimension reduction, SUVmax reduction and reduction of HF1*α*-positive cells after trastuzmab is shown in **D**--**F**) respectively. Group analysis according to HIF1*α* status (low *vs* high) of percentage reduction of PET dimensions is shown in [Figure 1G](#fig1){ref-type="fig"}. Group analysis according to HER2 status (low *vs* high) of percentage reduction of SUVmax is shown in (**H**). Bars show standard errors and midline the mean value.](bjc2014196f3){#fig3}

![**Changes of the immunohistochemical profile of tumours after one cycle of Trastuzumab therapy.** (**A**) Ki67 and GLUT1; (**B**) HER2, LC3A and LC3B; (**C**) combined HER2/LC3A and HER2/LC3B. Initial pre-therapy content of HIF1*α*- (**D**) and of PgR-positive cells (**E**) according to response to Trastuzumab plus taxol therapy (bars show standard errors and midline the mean value.](bjc2014196f4){#fig4}

###### Patient and disease characteristics

                                       **No of patients**
  ------------------------------------ --------------------
  **Menopausal status**                
  Pre                                  11
  Post                                 17
  **Histology**                        
  NOS                                  24
  Lobular                              4
  **Clinical T-stage**                 
  1                                    3
  2                                    16
  3                                    7
  4                                    2
  **Clinical nodal status**            
  Negative                             14
  Positive                             10
  Doubtful                             4
  **Histology grade**                  
  1, 2                                 7
  3                                    21
  **Oestrogen receptor % +cells**      
  0--20%                               16
  30--100%                             12
  **Progesterone receptor % +cells**   
  0--20%                               21
  30--100%                             6
  Unknown                              1
